WO2026027920 - A NOVEL TOPICAL ERADICATION FOR SKIN DISEASE
National phase entry is expected:
Publication Number
WO/2026/027920
Publication Date
05.02.2026
International Application No.
PCT/IB2024/057362
International Filing Date
30.07.2024
Title **
[English]
A NOVEL TOPICAL ERADICATION FOR SKIN DISEASE
[French]
NOUVELLE ÉRADICATION TOPIQUE POUR MALADIE DE LA PEAU
Applicants **
BALKANAS, Nikos
Inventors
BALKANAS, Nikos
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1806 | |
| EPO | Filing, Examination, Granting | 6239 | |
| Japan | Filing, Examination, Granting | 1860 | |
| South Korea | Filing, Examination, Granting | 1344 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
17,189
Contact Us
Abstract[English]
The presented invention is meant to replace all traditional treatments for the skin (topical, systemic), It is developed for oily skin, but can be used by anyone. Unlike traditional treatment it is effective all of the time. Consists of a 2-phase solution, emulsion or liposomes, that is topical. The 2 phases can be adjusted independently, as long as droplet size are smaller than skin pores (20-150μm) and have the right surface polarity to enter skin pores for effective treatment. It is better than existing systemic treatments by the ratio of drug solubilities, typically by 100x. By reducing the drug phase, droplet size is reduced for easier skin pore emtry and if organic don't cause skin burns.[French]
La présente invention vise à remplacer tous les traitements classiques de la peau (topiques, systémiques). Elle est développée pour la peau grasse, mais peut être utilisée par tout le monde. Contrairement au traitements classiques, elle est efficace en permanence. Elle est constituée de liposomes, d'une émulsion ou d'une solution à deux phases, qui sont topiques. Les deux phases peuvent être ajustées indépendamment, tant que les gouttelettes ont une taille inférieure à celle des pores de la peau (20 à 150 µm) et qu'elles ont la bonne polarité de surface pour pénétrer dans les pores de la peau pour un traitement efficace. Elle est supérieure aux traitements systémiques existants en termes de rapport des solubilités de médicament, généralement de 100 fois. En réduisant la phase médicamenteuse, la taille des gouttelettes est réduite pour faciliter la pénétration dans les pores de la peau et, si elles sont organiques, elles ne provoquent pas de brûlures cutanées.